Aura Biosciences (AURA) Equity Average (2020 - 2026)
Aura Biosciences filings provide 7 years of Equity Average readings, the most recent being $122.1 million for Q1 2026.
- Quarterly Equity Average fell 12.78% to $122.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $122.1 million through Mar 2026, down 12.78% year-over-year, with the annual reading at $144.4 million for FY2025, 23.54% down from the prior year.
- Equity Average hit $122.1 million in Q1 2026 for Aura Biosciences, down from $146.8 million in the prior quarter.
- Across five years, Equity Average topped out at $217.3 million in Q1 2024 and bottomed at $122.1 million in Q3 2022.
- Average Equity Average over 5 years is $162.2 million, with a median of $159.1 million recorded in 2023.
- The largest annual shift saw Equity Average soared 1358.39% in 2022 before it tumbled 35.59% in 2025.
- Aura Biosciences' Equity Average stood at $155.3 million in 2022, then increased by 21.55% to $188.8 million in 2023, then dropped by 13.49% to $163.3 million in 2024, then dropped by 10.12% to $146.8 million in 2025, then dropped by 16.83% to $122.1 million in 2026.
- Per Business Quant, the three most recent readings for AURA's Equity Average are $122.1 million (Q1 2026), $146.8 million (Q4 2025), and $165.6 million (Q3 2025).